Advanced Life Sciences Holdings, Inc. to Present at BioFinance Canada 2007 and Announces Filing of Annual Report on Form 10-K

WOODRIDGE, Ill., March 30 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. today announced that it will present at BioFinance Canada 2007, the Canadian Life Science industry's leading investor conference. Advanced Life Sciences' management was invited to present by the State of Illinois' Department of Commerce and Economic Opportunity, which is a sponsor of the event. The Company's presentation will be delivered at 10:30 AM Eastern Daylight Time in the Trinity IV room on Wednesday, April 25, 2007 at The Toronto Marriott Eaton Centre in Toronto, Ontario.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )

Advanced Life Sciences Holdings, Inc. recently announced its fourth quarter and full year 2006 results and filed its Form 10-K for the year ended December 31, 2006 with the U.S. Securities and Exchange Commission on March 22, 2007. Pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B), the Company is announcing that it has received a going concern qualification in the auditors' report on the financial statements contained in the Company's Form 10-K. This announcement does not represent any change or amendment to the Company's 2006 financial statements or to its Annual Report on Form 10-K.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a second generation ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

Visit us on the web at http://www.advancedlifesciences.com .

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAdvanced Life Sciences Holdings, Inc.

CONTACT: Edward P. Flavin of Advanced Life Sciences Holdings,+1-630-739-6744

Web site: http://www.advancedlifesciences.com/